Bispecific therapeutics for ophthalmic indications: Target selection and the optimal molecular format

Expert Review of Ophthalmology

Volumn 9, Issue 3, 2014, Pages 217-225

  Le Couter, Jennifer ^a   Scheer, Justin M ^a  

^a GENENTECH INC   (United States)

Author keywords

Age related macular degeneration; Antibody platform; Bispecific antibody; Diabetic macular edema; Diabetic retinopathy; Dry AMD; Geographic atrophy; Intravitreal delivery; Neovascular AMD; Protein technologies; VEGF

Indexed keywords

AFLIBERCEPT; ANKYRIN; APTAMER; BEVACIZUMAB; BISPECIFIC ANTIBODY; E 10030; FOVISTA; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MOLECULAR SCAFFOLD; MP 0260; PEGAPTANIB; RANIBIZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE FC SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

BIOLOGICAL THERAPY; CORNEA NEOVASCULARIZATION; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; IC 50; NONHUMAN; PATHOPHYSIOLOGY; RETINA MACULA AGE RELATED DEGENERATION; RETINOPATHY; REVIEW; SUBRETINAL NEOVASCULARIZATION;

EID: 84901263428     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2014.918846     Document Type: Review

References (55)

1. van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 2014; 232(2):151-64
2. Bressler N. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1 (Pubitemid 38509505
3. Bressler N, Doan Q, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 2011;129:709-17
4. Rein D, Wittenborn J, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments. Arch Ophthalmol 2009;127:533-40
5. Klein R, Lees K, Gangnon R, Klein B. The 25-year incidence of visual impairment in Type 1 Diabetes Mellitus: The Wisconsin study of diabetic retinopathy. Ophthalmology 2010;117:63-70
6. Holz F, Strauss E, Schmitz-Valckenberg S, Campagne MvL. Geographic atrophy: Clinical features and potential therapeutic approaches. Ophthalmology 2014. [Epub ahead of print]
7. Prevention CfDCa. Centers for Disease Control and Prevention: 2011 National Diabetes Fact Sheet. 2011
8. Yau J, Rogers S, Kawasaki R, et al. The global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64
9. Rumkumar H, Zhang J, Chan C. Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). Prog Retin Eye Res 2010;29:169-90
10. Oliner J, Bready J, Nguyen L, et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases. Invest Ophthalmol Vis Sci 2012;53:2170-80
11. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507-16 (Pubitemid 39469986
12. Rennel E, Regula J, Harper S, et al. A human neutralizing antibody specific to ANG-2 inhibits ocular angiogenesis. Microcirculation 2011;18:598-607
13. Jo N, Maihos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168: 2036-53 (Pubitemid 43825322
14. Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-Tie signaling pathway. Cold Spring Harb Perspect Med 2012;2:1-13
15. Cabrillo S, Swaney J, Moreno K, et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res 2009;88:367-77
16. O'Brien N, Jones S, Williams D, et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res 2009;50:2245-57
17. Yao Z, West D, Kuebler P, et al. Prevention of laser photocoagulation induced choroidal neovascularization lesions by intravitreal doses of ranibizumab in cynomolgus monkeys. In: 2009 Annual Meeting ARVO. Ft. Lauderdale, FL, USA; 2009
18. Yu L, Cheng Z, Wu X, et al. Interaction between bevacizumab and murine VEGF-A: A reassessment. Invest Ophthalmol Vis Sci 2008;49:522-7
19. Jakobsdottir J, Conley Y, Weeks D, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005;77:389-407 (Pubitemid 41192646
20. Rivera A, Fisher S, Fritsche L, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005;14:3227-36 (Pubitemid 41631297
21. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10(5):301-16
22. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321(5891):974-7
23. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-Term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123(3): 356-65
24. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69(12):4941-4
25. Castoldi R, Ecker V, Wiehle L, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 2013;32(50):5593-601
26. Spiess C, Merchant M, Huang A, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-Antibodies. Nat Biotechnol 2013;31(8): 753-8
27. Kienast Y, Klein C, Scheuer W, et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 2013;19(24):6730-40
28. Wu C, Ying H, Bose S, et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009;1(4):339-47
29. McAleese F, Eser M. RECRUIT-TandAbs: Harnessing the immune system to kill cancer cells. Future Oncol 2012;8(6):687-95
30. Hess J, Ruf P, Lindhofer H. Cancer therapy with trifunctional antibodies: Linking innate and adaptive immunity. Future Oncol 2012;8(1):73-85
31. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27(9):1260-6 (Pubitemid 350211535
32. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46(2):726-33 (Pubitemid 40270359
33. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009;15:2803-12
34. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50(10):4807-13
35. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128(10):1273-9
36. Comparison of age-related macular degeneration treatments trials research group. Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119(7):1388-98
37. Stahl A, Stumpp MT, Schlegel A, et al. Highly potent VEGF-A-Antagonistic DARPins as anti-Angiogenic agents for topical and intravitreal applications. Angiogenesis 2012;16(1):101-11
38. Tobin KA. Macugen treatment for wet age-related macular degeneration. Insight 2006;31(1):11-14 (Pubitemid 44971755
39. Labrijn AF, Meesters JI, de Goeij BE, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-Arm exchange. Proc Natl Acad Sci U S A 2013;110(13):5145-50
40. Schaefer W, Regula JT, Bahner M, et al. Immunoglobulin Domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011;108(27):11187-92
41. Strop P, Ho WH, Boustany LM, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012;420(3):204-19
42. Boersma YL, Chao G, Steiner D, et al. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 2011;286(48):41273-85
43. Mabry R, Gilbertson DG, Frank A, et al. A dual-Targeting PDGFRbeta/VEGFA molecule assembled from stable antibody fragments demonstrates anti-Angiogenic activity in vitro and in vivo. MAbs 2010; 2(1):20-34
44. Dreier B, Mikheeva G, Belousova N, et al. Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting. J Mol Biol 2011;405(2):410-26
45. Eggel A, Baumann MJ, Amstutz P, et al. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol 2009;393(3):598-607
46. Eggel A, Buschor P, Baumann MJ, et al. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 2011;66(7):961-8
47. Friedrich K, Hanauer JR, Prufer S, et al. DARPin-Targeting of measles virus: Unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther 2013;21(4): 849-59
48. Dong A SC, Snell D, Ekawardhani S, et al. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. Angiogenesis 2013. [Epub ahead of print]
49. Binz HK, Amstutz P, Kohl A, et al. High-Affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22(5):575-82 (Pubitemid 38590636
50. Dreier B, Honegger A, Hess C, et al. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A 2013; 110(10):E869-77
51. El Sanharawi M, Kowalczuk L, Touchard E, et al. Protein Delivery for retinal diseases: From basic considerations to clinical applications. Prog Retin Eye Res 2010; 29(6):443-65
52. Eigenbrot C, Fuh G. Two-in-One antibodies with dual action Fabs. Curr Opin Chem Biol 2013;17(3):400-5
53. Ellerman D, Scheer JM. Generation of bispecific antibodies by chem0ical conjugation. In: Bispecific Antibodies. Springer, Heidelberg; 2011. p. 47-63
54. Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs 2012;4(2): 182-97
55. BioCentury. Available from: Www. biocentury.com/products/mp0260